Prostate-specific antigen-retargeted recombinant newcastle disease virus for prostate cancer virotherapy

Journal of Virology

Volumn 87, Issue 7, 2013, Pages 3792-3800

  Shobana, Raghunath ^a   Samal, Siba K ^b   Elankumaran, Subbiah ^a  

^a VIRGINIA MARYLAND REGIONAL COLLEGE OF VETERINARY MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; METRIBOLONE; PROSTATE SPECIFIC ANTIGEN; PROTEIN F; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; ARTICLE; BIOENGINEERING; CANCER CELL; CHICKEN; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOLYSIS; EMBRYO; HUMAN; HUMAN CELL; NEWCASTLE DISEASE; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN CLEAVAGE; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS VIRULENCE;

ANALYSIS OF VARIANCE; ANIMALS; BASE SEQUENCE; CERCOPITHECUS AETHIOPS; CHICK EMBRYO; FLOW CYTOMETRY; GENE TARGETING; HUMANS; IMMUNOBLOTTING; MALE; METRIBOLONE; MICROSCOPY, FLUORESCENCE; MOLECULAR SEQUENCE DATA; NEWCASTLE DISEASE VIRUS; ONCOLYTIC VIROTHERAPY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN ENGINEERING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA; VERO CELLS; VIRAL FUSION PROTEINS; VIRUS REPLICATION;

AVES; GALLUS GALLUS; NEWCASTLE DISEASE VIRUS; PARAMYXOVIRIDAE;

EID: 84875519860     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02394-12     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. 2009. Cancer statistics, 2009. CA Cancer J. Clin. 59:225-249.
2. Cattaneo R, Miest T, Shashkova EV, Barry MA. 2008. Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat. Rev. Microbiol. 6:529 -540.
3. Guo ZS, Thorne SH, Bartlett DL. 2008. Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim. Biophys. Acta 1785:217-231.
4. Freeman AI, Zakay-Rones Z, Gomori JM, Linetsky E, Rasooly L, Greenbaum E, Rozenman-Yair S, Panet A, Libson E, Irving CS, Galun E, Siegal T. 2006. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol. Ther. 13:221-228.
5. Lam HY, Yeap SK, Rasoli M, Omar AR, Yusoff K, Suraini AA, Alitheen NB. 2011. Safety and clinical usage of Newcastle disease virus in cancer therapy. J. Biomed. Biotechnol. 2011:718710. doi:10.1155/2011/718710.
6. Lorence RM, Roberts MS, O'Neil JD, Groene WS, Miller JA, Mueller SN, Bamat MK. 2007. Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus. Curr. Cancer Drug Targets 7:157-167.
7. Sergel-Germano T, McQuain C, Morrison T. 1994. Mutations in the fusion peptide and heptad repeat regions of the Newcastle disease virus fusion protein block fusion. J. Virol. 68:7654 -7658.
8. Akiyama K, Nakamura T, Iwanaga S, Hara M. 1987. The chymotrypsinlike activity of human prostate-specific antigen, gamma-seminoprotein. FEBS Lett. 225:168 -172.
9. Christensson A, Laurell CB, Lilja H. 1990. Enzymatic activity of prostatespecific antigen and its reactions with extracellular serine proteinase inhibitors. Eur. J. Biochem. 194:755-763.
10. Lilja H, Christensson A, Dahlen U, Matikainen MT, Nilsson O, Pettersson K, Lovgren T. 1991. Prostate-specific antigen in serum occurs predominantly in complex with α1-antichymotrypsin. Clin. Chem. 37: 1618-1625.
11. Otto A, Bar J, Birkenmeier G. 1998. Prostate-specific antigen forms complexes with human α2-macroglobulin and binds to the α2- macroglobulin receptor/LDL receptor-related protein. J. Urol. 159:297- 303.
12. Lilja H, Abrahamsson PA, Lundwall A. 1989. Semenogelin, the predominant protein in human semen. Primary structure and identification of closely related proteins in the male accessory sex glands and on the spermatozoa. J. Biol. Chem. 264:1894 -1900.
13. Weir EG, Partin AW, Epstein JI. 2000. Correlation of serum prostate specific antigen and quantitative immunohistochemistry. J. Urol. 163: 1739-1742.
14. McCormack RT, Rittenhouse HG, Finlay JA, Sokoloff RL, Wang TJ, Wolfert RL, Lilja H, Oesterling JE. 1995. Molecular forms of prostatespecific antigen and the human kallikrein gene family: a new era. Urology 45:729 -744.
15. Denmeade SR, Sokoll LJ, Chan DW, Khan SR, Isaacs JT. 2001. Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models. Prostate 48:1- 6.
16. Vukmirovic-Popovic S, Escott NG, Duivenvoorden WC. 2008. Presence and enzymatic activity of prostate-specific antigen in archival prostate cancer samples. Oncol. Rep. 20:897-903.
17. Kinoh H, Inoue M. 2008. New cancer therapy using geneticallyengineered oncolytic Sendai virus vector. Front. Biosci. 13:2327-2334.
18. Springfeld C, von Messling V, Frenzke M, Ungerechts G, Buchholz CJ, Cattaneo R. 2006. Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases. Cancer Res. 66: 7694-7700.
19. Collins MS, Bashiruddin JB, Alexander DJ. 1993. Deduced amino acid sequences at the fusion protein cleavage site of Newcastle disease viruses showing variation in antigenicity and pathogenicity. Arch. Virol. 128:363- 370.
20. Denmeade SR, Lou W, Lovgren J, Malm J, Lilja H, Isaacs JT. 1997. Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen. Cancer Res. 57:4924-4930.
21. Singh P, LeBeau AM, Lilja H, Denmeade SR, Isaacs JT. 2009. Molecular insights into substrate specificity of prostate specific antigen through structural modeling. Proteins 77:984 -993.
22. Morrison T, McQuain C, Sergel T, McGinnes L, Reitter J. 1993. The role of the amino terminus of F1 of the Newcastle disease virus fusion protein in cleavage and fusion. Virology 193:997-1000.
23. Buchholz UJ, Finke S, Conzelmann KK. 1999. Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. J. Virol. 73:251-259.
24. Elankumaran S, Rockemann D, Samal SK. 2006. Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death. J. Virol. 80:7522-7534.
25. Kohn A. 1965. Polykaryocytosis induced by Newcastle disease virus in monolayers of animal cells. Virology 26:228 -245.
26. Altman SA, Randers L, Rao G. 1993. Comparison of trypan blue dye exclusion and fluorometric assays for mammalian cell viability determinations. Biotechnol. Prog. 9:671- 674.
27. Tennant JR. 1964. Evaluation of the trypan blue technique for determination of cell viability. Transplantation 2:685- 694.
28. Huang Z, Panda A, Elankumaran S, Govindarajan D, Rockemann DD, Samal SK. 2004. The hemagglutinin-neuraminidase protein of Newcastle disease virus determines tropism and virulence. J. Virol. 78:4176-4184.
29. Krishnamurthy S, Huang Z, Samal SK. 2000. Recovery of a virulent strain of Newcastle disease virus from cloned cDNA: expression of a foreign gene results in growth retardation and attenuation. Virology 278: 168-182.
30. Flint SJ, Enquist LW, Racaniello VR, Skalka AM. 2009. Principles of virology: molecular biology, pathogenesis, and control of animal viruses, 3rd ed, p 32-37. ASM Press, Washington, DC.
31. Alexander DJ. 1988. Newcastle disease diagnosis. In Alexander DJ (ed), Newcastle disease. Kluwer Academic Publishers, Boston, MA.
32. Elankumaran S, Chavan V, Qiao D, Shobana R, Moorkanat G, Biswas M, Samal SK. 2010. Type I interferon-sensitive recombinant Newcastle disease virus for oncolytic virotherapy. J. Virol.
33. Biswas M, Kumar SR, Allen A, Yong W, Nimmanapalli R, Samal SK, Elankumaran S. 2012. Cell-type-specific innate immune response to oncolytic Newcastle disease virus. Viral Immunol. 25:268 -276.
34. de Leeuw OS, Koch G, Hartog L, Ravenshorst N, Peeters BP. 2005. Virulence of Newcastle disease virus is determined by the cleavage site of the fusion protein and by both the stem region and globular head of the haemagglutinin-neuraminidase protein. J. Gen. Virol. 86:1759 -1769.
35. Goettig P, Magdolen V, Brandstetter H. 2010. Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs). Biochimie 92:1546- 1567.
36. Neri A, Bohoslawec O, Anderson TD, Tokes ZA. 1991. Differential release of active proteinase inhibitors by two rat mammary adenocarcinoma variants possessing different metastatic potentials. Cancer Res. 51: 1318-1325.
37. Christensson A, Lilja H. 1994. Complex formation between protein C inhibitor and prostate-specific antigen in vitro and in human semen. Eur. J. Biochem. 220:45-53.
38. Huber PR, Mattarelli G, Strittmatter B, van Steenbrugge GJ, Schmid HP, Maurer A. 1995. In vivo and in vitro complex formation of prostate specific antigen with α1-anti-chymotrypsin. Prostate 27:166 -175.
39. Bauer JA, Thompson TA, Church DR, Ariazi EA, Wilding G. 2003. Growth inhibition and differentiation in human prostate carcinoma cells induced by the vitamin D analog 1α,24-dihydroxyvitamin D2. Prostate 55:159 -167.
40. Freyer JP, Sutherland RM. 1980. Selective dissociation and characterization of cells from different regions of multicell tumor spheroids. Cancer Res. 40:3956 -3965.
41. Kostarelos K, Emfietzoglou D, Papakostas A, Yang WH, Ballangrud A, Sgouros G. 2004. Binding and interstitial penetration of liposomes within avascular tumor spheroids. Int. J. Cancer 112:713-721.
42. Sutherland RM. 1988. Cell and environment interactions in tumor microregions: the multicell spheroid model. Science 240:177-184.
43. Han J, Chang H, Giricz O, Lee GY, Baehner FL, Gray JW, Bissell MJ, Kenny PA, Parvin B. 2010. Molecular predictors of 3D morphogenesis by breast cancer cell lines in 3D culture. PLoS Comput. Biol. 6:e1000684. doi:10.1371/journal.pcbi.1000684.
44. Härmä V, Virtanen J, Mäkelä R, Happonen A, Mpindi JP, Knuuttila M, Kohonen P, Lötjönen J, Kallioniemi O, Nees M. 2010. A comprehensive panel of three-dimensional models for studies of prostate cancer growth, invasion and drug responses. PLoS One 5:e10431. doi:10.1371/journal .pone.0010431.
45. Kenny PA, Lee GY, Myers CA, Neve RM, Semeiks JR, Spellman PT, Lorenz K, Lee EH, Barcellos-Hoff MH, Petersen OW, Gray JW, Bissell MJ. 2007. The morphologies of breast cancer cell lines in threedimensional assays correlate with their profiles of gene expression. Mol. Oncol. 1:84 -96.
46. Lee GY, Kenny PA, Lee EH, Bissell MJ. 2007. Three-dimensional culture models of normal and malignant breast epithelial cells. Nat. Methods 4:359 -365.
47. Chandran SS, Nan A, Rosen DM, Ghandehari H, Denmeade SR. 2007. A prostate-specific antigen activated N-(2-hydroxypropyl) methacrylamide copolymer prodrug as dual-targeted therapy for prostate cancer. Mol. Cancer Ther. 6:2928 -2937.
48. Denmeade SR, Nagy A, Gao J, Lilja H, Schally AV, Isaacs JT. 1998. Enzymatic activation of a doxorubicin-peptide prodrug by prostatespecific antigen. Cancer Res. 58:2537-2540.
49. Khan SR, Denmeade SR. 2000. In vivo activity of a PSA-activated doxorubicin prodrug against PSA-producing human prostate cancer xenografts. Prostate 45:80-83.
50. Biswas M, Johnson JB, Kumar SR, Parks GD, Elankumaran S. 2012. Incorporation of host complement regulatory proteins into Newcastle disease virus enhances complement evasion. J. Virol. 86:12708 -12716.